Leo Pharma and PellePharm sign rare disease deal

Denmark-based Leo Pharma and Californian rare disease company PellePharm have partnered to develop and commercialise therapies for rare forms of skin cancer.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Teva can pursue monopoly claims over rival’s ‘exclusive pharmacy deal’

7 May 2026 A California judge has denied Corcept’s bid to dismiss the lawsuit over its drug for a rare hormonal disorder, allowing the litigation to proceed on all core counts.

Americas

US judge allows rare patent defence in ‘world’s smallest heart pump’ suit

5 May 2026 J&J’s Abiomed can proceed with its non-infringement defence despite potential future appellate reversal, in a week when both parties in the case were dealt wins and losses in their clash over Impella devices.

Americas

WATCH: Interview with Ben Doranz, president and CEO, Integral Molecular

4 May 2026 LSIPR's senior reporter Marisa Woutersen speaks with Ben Doranz of Integral Molecular, fresh from the stage at LSPN Boston after speaking at a panel session on challenges in antibody patent protection.

More features

IP in the deal room: The risks that bite before, during and after closing

Teva can pursue monopoly claims over rival’s ‘exclusive pharmacy deal’

Five generations at work: How teams are bridging the gap

Kilpatrick adds tech patent litigator and China expert to Chicago office

US judge allows rare patent defence in ‘world’s smallest heart pump’ suit

WATCH: John Ward, trademarks VP and associate GC of Moderna, at INTA

WATCH: Interview with Ben Doranz, president and CEO, Integral Molecular

Brussels under scrutiny for IP policy as US flags risks to innovation

Leo Pharma and PellePharm sign rare disease deal

More on this story

Editor's picks

Editor's picks

More features